Adaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Update

Adaptimmune Therapeutics plc (NASDAQ:ADAP) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 3,410,000 shares, a growth of 6.6% from the March 31st total of 3,200,000 shares. Based on an average daily trading volume, of 1,970,000 shares, the days-to-cover ratio is presently 1.7 days.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ADAP. Marquette Asset Management LLC purchased a new position in shares of Adaptimmune Therapeutics in the 3rd quarter valued at approximately $77,000. Key Client Fiduciary Advisors LLC grew its stake in shares of Adaptimmune Therapeutics by 6.4% in the 4th quarter. Key Client Fiduciary Advisors LLC now owns 336,620 shares of the biotechnology company’s stock valued at $267,000 after purchasing an additional 20,295 shares during the last quarter. Harbor Capital Advisors Inc. grew its stake in shares of Adaptimmune Therapeutics by 9.9% in the 4th quarter. Harbor Capital Advisors Inc. now owns 147,732 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 13,317 shares during the last quarter. Acuitas Investments LLC purchased a new position in shares of Adaptimmune Therapeutics in the 3rd quarter valued at approximately $374,000. Finally, JTC Employer Solutions Trustee Ltd purchased a new position in shares of Adaptimmune Therapeutics in the 1st quarter valued at approximately $41,000. Hedge funds and other institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Stock Up 3.5 %

NASDAQ:ADAP opened at $1.19 on Wednesday. The stock’s 50 day moving average price is $1.38 and its 200 day moving average price is $0.94. The company has a market capitalization of $293.72 million, a PE ratio of -2.16 and a beta of 2.39. Adaptimmune Therapeutics has a 52-week low of $0.42 and a 52-week high of $2.05.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings results on Wednesday, March 6th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.12). The firm had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $4.80 million. Adaptimmune Therapeutics had a negative return on equity of 155.39% and a negative net margin of 188.90%. As a group, sell-side analysts anticipate that Adaptimmune Therapeutics will post -0.49 EPS for the current fiscal year.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.